CONSUN PHARMAC.GR.HD -10
Research CONSUN PHARMAC.GR.HD -10 (C1P) on Bullrun: market cap EUR 1.15B, P/E 8.6, dividend yield 6.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerC1P
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 1.15B
- P/E8.6
- Dividend yield6.2%
- Financial periodFY2025
- RevenueEUR 3.42B
- Revenue growth15.2%
- Net incomeEUR 1.08B
- Free cash flowEUR 1.14B
- Gross margin78.0%
Valuation Snapshot
latest market cap is EUR 1.15B; P/E is 8.6; dividend yield is 6.2%.
About CONSUN PHARMAC.GR.HD -10
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment;
Frequently asked questions
What is CONSUN PHARMAC.GR.HD -10's market cap?
CONSUN PHARMAC.GR.HD -10's market capitalization is EUR 1.15B.
What is CONSUN PHARMAC.GR.HD -10's P/E ratio?
CONSUN PHARMAC.GR.HD -10's price-to-earnings (P/E) ratio is 8.6.
Does CONSUN PHARMAC.GR.HD -10 pay a dividend?
CONSUN PHARMAC.GR.HD -10 has a dividend yield of 6.2%.
What does CONSUN PHARMAC.GR.HD -10 do?
Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure;